DYSLIPIDEMIA IN UREMIC PATIENTS TREATED WITH INTERMITTENT DIALYSIS [ ]


It is known that uremic patients present clinical atherosclerosis mirror the earlier representation and serious complications of cardiovascular, cerebrovascular with peripheral arterial injuries more frequently with many more younger compared with the healthy population. Recent years has been verified that uremic dyslipidemia persists that in the early stages of kidney weakness, prior to treatment with hemodialysis (HD) and is one of basic factors of the beginning of atherogenic processes in uremic patients. Lipid metabolism disorders in patients with ESRD is first described in 1827 by Dr. Bright, especially in patients with nephrotic syndrome. Replacingphysiological lipoapoproteins with those pathological and effect of their high atherogenic impact phenomena are still undiscovered. Metabolism disorders of HDL-ch is the main factor responsible for checking the progress and pace of atherogenesis in uremic patients.The purpose of this paper research is to evaluate the anomalies of lipids and apolipoproteins inuremic patients treated with hemodialysis over 7 years in the Department of Haemodialysis at the Clinical Hospital of Tetovo, randomized by gender, age and underlying disease that has led to uremia. Matherial and methods; In our study are included 120 patients (66 male and 54 female) with ESRD treated with hemodialysis in Clinical Hospital in Tetovo, Nephrology and Hemodialysis Unit.